Ad hoc Press Release

Ad hoc Press Release According to § 15 WphG

MediGene sells full European rights for Eligard® to Astellas for EUR 25 million and ongoing royalties  2010-07-19 Ad hoc: MediGene publishes first, preliminary results obtained in a phase II clinical trial of EndoTAG(TM)-1 for the treatment of triple receptor-negative breast cancer  2010-05-06 MediGene AG Decides on a Revision of the Development Plans for EndoTAGTM-1 and RhuDexTM, and Downsizes its Executive Board  2009-12-11 RhuDex™ Clinical Development to Continue Following Feedback from Regulatory Authorities  2009-10-05 MediGene Sharpens Focus through In-House Reorganization  2009-09-28 MediGene receives Positive Decisions on Market Approval for Veregen® in First European Countries   2009-07-10 MediGene AG Appoints Dr. Frank Mathias as new Chief Executive Officer   2009-04-29 MediGene to be Listed on TecDAX Index  2009-02-05

For further information please contact Julia Hofmann or Georg Dönges, Public Relations, MediGene AG Contact